Doptelet — Medical Mutual

Reauthorization criteria

• Age ≥ 18 years; AND
• Has had a platelet response after 4 weeks of Doptelet therapy as evidenced by platelet count > 50,000/mcL; AND
• Patient is not using Doptelet in combination with another therapy for chronic immune thrombocytopenia (for example: Promacta, Nplate); AND
• Doptelet is prescribed by or in consultation with a hematologist

Approval duration

6 months